---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-086428"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2025-09-02T23:59:59+00:00"
generated_at: "2026-05-17T08:52:55.280444+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA issues Complete Response Letter to Outlook Therapeutics for ONS-5010 BLA; lacks efficacy evidence

## Summary
- CRL cites lack of substantial evidence of effectiveness; ONS-5010 did not meet primary endpoint in NORSE EIGHT trial.
- FDA recommends confirmatory evidence; NORSE TWO met primary endpoint but is not sufficient alone.
- No other deficiencies in BLA; company plans to meet with FDA to discuss possible path to approval.
- ONS-5010/LYTENAVA already approved in EU and UK; commercial launch in Germany and UK began June 2025.

## SEC filing metadata
- accession: 0001104659-25-086428
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2025-09-02T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465925086428/0001104659-25-086428-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465925086428/tm2524956d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-086428
- JSON: https://secwatch.observer/filing/0001104659-25-086428.json
- Plain text: https://secwatch.observer/filing/0001104659-25-086428.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.